secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2026-08-04T01:00:20+00:00
Accession:  0001193125-26-331138
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus to be acquired by Curium for $102.50/share plus up to $12.00 in CVRs
-----------------------------------------------------------------------------

- Total consideration up to $114.50/share: $102.50 cash plus CVRs tied to commercial milestones for prostate cancer, neurology, and DEFINITY franchises.
- CVR milestones: Global Prostate Cancer Diagnostics sales >$950M triggers $1/share, up to $2/share for >$1.75B.
- Transaction expected to close by May 2, 2027, subject to stockholder and regulatory approvals; no financing condition.
- Termination fees: Parent pays $385M (or $100M regulatory) to Lantheus; Lantheus pays $228M to Parent.
- Board approved $6M transaction bonus pool; $4M to CEO Mary Anne Heino and $500K to CFO Daniel Niedzwiecki, payable at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/0001193125-26-331138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312526331138/d167446d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer